The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS42767
• Study ID:
  49036
• Official title and acronym:
  The European HBV Registry: A joint initiative of TherVacB and DZIF (HBV Registry)
• DARWIN EU® study:
  No
• Study countries:
  Germany

  Italy

  Spain

  United Kingdom
• Study description:
  In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. ; The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials. Extensive analyses of virus and host-specific parameters are to be carried out from these patients. ; The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies. ; Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Hannover Medical School (MHH)

University Medical Centre Hamburg-Eppendorf

Germany

Heidelberg University Hospital

TUM-MRI Munich, Germany; UK Leipzig Leipzig, Germany; FCRB Barcelona, Spain; AOP Parma, Italy; RFH London, UK; BLT London, UK; UK Mannheim, Germany

Networks

TherVacB, DZIF

Study timelines

Date when funding contract was signed

Actual:01/01/2020

Study start date

Actual:06/05/2021

Date of final study report

Planned:31/12/2030

Sources of funding

EU institutional research programme

Other

More details on funding

BMBF, Horizon 2020

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable